Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Cinacalcet sustainedly prevents pancreatitis in a child with a compound heterozygous SPINK1/AP2S1 mutation.

Scheers I, Sokal E, Limaye N, Denoncin C, Stephenne X, Pirson Y, Godefroid N.

Pancreatology. 2019 Sep;19(6):801-804. doi: 10.1016/j.pan.2019.07.045. Epub 2019 Jul 30.

PMID:
31391146
2.

Genotype and Outcome After Kidney Transplantation in Alport Syndrome.

Gillion V, Dahan K, Cosyns JP, Hilbert P, Jadoul M, Goffin E, Godefroid N, De Meyer M, Mourad M, Pirson Y, Kanaan N.

Kidney Int Rep. 2018 Feb 2;3(3):652-660. doi: 10.1016/j.ekir.2018.01.008. eCollection 2018 May.

3.

Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation.

Kanaan N, Raggi C, Goffin E, De Meyer M, Mourad M, Jadoul M, Beguin C, Kabamba B, Borbath I, Pirson Y, Hassoun Z.

J Viral Hepat. 2017 May;24(5):430-435. doi: 10.1111/jvh.12655. Epub 2016 Dec 5.

PMID:
27917563
4.

International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection.

Lantinga MA, Darding AJ, de Sévaux RG, Alam A, Bleeker-Rovers CP, Bobot M, Cornec-Le Gall E, Gevers TJ, Hassoun Z, Meijer E, Mrug M, Nevens F, Onuchic LF, Pei Y, Piccoli GB, Pirson Y, Rangan GK, Torra R, Visser FW, Jouret F, Kanaan N, Oyen WJ, Suwabe T, Torres VE, Drenth JP; Delphi collaborators.

Nephron. 2016;134(4):205-214. Epub 2016 Sep 3.

PMID:
27599120
5.

Complement activation and effect of eculizumab in scleroderma renal crisis.

Devresse A, Aydin S, Le Quintrec M, Demoulin N, Stordeur P, Lambert C, Gastoldi S, Pirson Y, Jadoul M, Morelle J.

Medicine (Baltimore). 2016 Jul;95(30):e4459. doi: 10.1097/MD.0000000000004459.

6.

Clinical and mutational spectrum of hypoparathyroidism, deafness and renal dysplasia syndrome.

Belge H, Dahan K, Cambier JF, Benoit V, Morelle J, Bloch J, Vanhille P, Pirson Y, Demoulin N.

Nephrol Dial Transplant. 2017 May 1;32(5):830-837. doi: 10.1093/ndt/gfw271.

PMID:
27387476
7.

Calcineurin Inhibitors Downregulate HNF-1β and May Affect the Outcome of HNF1B Patients After Renal Transplantation.

Faguer S, Esposito L, Casemayou A, Pirson Y, Decramer S, Cartery C, Hazzan M, Garrigue V, Roussey G, Cointault O, Ho T, Merville P, Devuyst O, Gourdy P, Chassaing N, Bascands JL, Kamar N, Schanstra JP, Rostaing L, Chauveau D.

Transplantation. 2016 Sep;100(9):1970-8. doi: 10.1097/TP.0000000000000993.

8.

Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.

Temmerman F, Ho TA, Vanslembrouck R, Coudyzer W, Billen J, Dobbels F, van Pelt J, Bammens B, Pirson Y, Nevens F.

Clin Gastroenterol Hepatol. 2015 Dec;13(13):2353-9.e1. doi: 10.1016/j.cgh.2015.05.039. Epub 2015 Jun 12.

PMID:
26073493
9.

Weight loss in a patient with polycystic kidney disease: when liver cysts are no longer innocent bystanders.

Cecere N, Hakem S, Demoulin N, Hubert C, Jabbour N, Goffette P, Pirson Y, Morelle J.

Acta Clin Belg. 2015 Oct;70(5):369-71. doi: 10.1179/2295333715Y.0000000024. Epub 2015 Apr 12.

PMID:
25866379
10.

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC; Conference Participants.

Kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18.

11.

[Infectious complications in autosomal dominant polycystic kidney disease].

Pirson Y, Kanaan N.

Nephrol Ther. 2015 Apr;11(2):73-7. doi: 10.1016/j.nephro.2014.11.008. Epub 2015 Feb 27. French.

PMID:
25733396
12.

Paradoxical response to furosemide in uromodulin-associated kidney disease.

Labriola L, Olinger E, Belge H, Pirson Y, Dahan K, Devuyst O.

Nephrol Dial Transplant. 2015 Feb;30(2):330-5. doi: 10.1093/ndt/gfu389. Epub 2014 Dec 23.

13.

Building a network of ADPKD reference centres across Europe: the EuroCYST initiative.

Petzold K, Gansevoort RT, Ong AC, Devuyst O, Rotar L, Eckardt KU, Köttgen A, Pirson Y, Remuzzi G, Sandford R, Tesar V, Ecder T, Chaveau D, Torra R, Budde K, Le Meur Y, Wüthrich RP, Serra AL.

Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv26-32. doi: 10.1093/ndt/gfu091. Erratum in: Nephrol Dial Transplant. 2014 Dec;29(12):2353.

14.

Development and validation of a polycystic liver disease complaint-specific assessment (POLCA).

Temmerman F, Dobbels F, Ho TA, Pirson Y, Vanslembrouck R, Coudyzer W, Bammens B, van Pelt J, Pirenne J, Nevens F.

J Hepatol. 2014 Nov;61(5):1143-50. doi: 10.1016/j.jhep.2014.06.024. Epub 2014 Jul 1.

PMID:
24996047
15.

Renal transplantation in autosomal dominant polycystic kidney disease.

Kanaan N, Devuyst O, Pirson Y.

Nat Rev Nephrol. 2014 Aug;10(8):455-65. doi: 10.1038/nrneph.2014.104. Epub 2014 Jun 17. Review.

PMID:
24935705
16.

Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.

Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, Guigonis V, Ducret F, Presne C, Pirson Y, Hourmant M, Glachant JC, Vendrely B, Moranne O, Faguer S, Chauveau D.

Nephrol Dial Transplant. 2014 Nov;29(11):2084-91. doi: 10.1093/ndt/gfu209. Epub 2014 Jun 11.

PMID:
24920841
17.

Acute oxalate nephropathy after renal transplantation.

Mazzoleni L, Aydin S, De Meyer M, Pirson Y, Kanaan N.

Acta Clin Belg. 2013 Sep-Oct;68(5):389. No abstract available.

PMID:
24579250
18.

Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.

Temmerman F, Gevers T, Ho TA, Vanslembrouck R, Coudyzer W, van Pelt J, Bammens B, Pirson Y, Drenth JP, Nevens F.

Aliment Pharmacol Ther. 2013 Aug;38(4):397-406. doi: 10.1111/apt.12384. Epub 2013 Jun 25.

19.

Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action.

Pirson Y.

Nephrol Dial Transplant. 2013 Jul;28(7):1680-5. doi: 10.1093/ndt/gft009. Epub 2013 Feb 14. Review. No abstract available.

PMID:
23413089
20.

Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.

Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van Biesen W, Vanholder R, Wanner C.

Nephrol Dial Transplant. 2013 Mar;28(3):505-17. doi: 10.1093/ndt/gfs526. Epub 2012 Dec 12.

21.

Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities.

Jouret F, Lhommel R, Devuyst O, Annet L, Pirson Y, Hassoun Z, Kanaan N.

Nephrol Dial Transplant. 2012 Oct;27(10):3746-51. doi: 10.1093/ndt/gfs352. Review.

22.

Night blindness in a haemodialysed ADPKD patient receiving octreotide.

Ho TA, Decleire PY, Lafontaine JJ, Pirson Y.

Clin Kidney J. 2012 Oct;5(5):474-5. doi: 10.1093/ckj/sfs121. No abstract available.

23.

Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection.

Kanaan N, Kabamba B, Maréchal C, Pirson Y, Beguin C, Goffin E, Hassoun Z.

J Clin Virol. 2012 Nov;55(3):233-8. doi: 10.1016/j.jcv.2012.07.015. Epub 2012 Aug 22.

PMID:
22921412
24.

Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.

Ho TA, Godefroid N, Gruzon D, Haymann JP, Maréchal C, Wang X, Serra A, Pirson Y, Devuyst O.

Kidney Int. 2012 Nov;82(10):1121-9. doi: 10.1038/ki.2012.225. Epub 2012 Jun 20.

25.

[Potentialisation of hyperkalemia effects by cinacalcet-induced hypocalcemia on dialysis].

Simon F, Bertrand Q, Pirson Y, Flamion B, Loute G.

Nephrol Ther. 2012 Nov;8(6):476-80. doi: 10.1016/j.nephro.2012.03.003. Epub 2012 Apr 18. French.

PMID:
22520484
26.

Pre-terminal renal insufficiency in a patient with enteric hyperoxaluria: effect of medical management on renal function.

Pipeleers L, Wissing KM, Pirson Y, Cosyns JP, Geers C, Tielemans C.

Acta Clin Belg. 2012 Jan-Feb;67(1):39-41.

PMID:
22480038
27.

Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations.

Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, Müller GA, Gross O.

Kidney Int. 2012 Apr;81(8):779-83. doi: 10.1038/ki.2011.452. Epub 2012 Jan 11.

28.

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.

Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, Höcker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, Dötsch J, Müller-Wiefel DE, Hoyer P; Study Group Members of the Gesellschaft für Pädiatrische Nephrologie, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Müller GA, Weber M.

Kidney Int. 2012 Mar;81(5):494-501. doi: 10.1038/ki.2011.407. Epub 2011 Dec 14.

29.

Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations.

Bollée G, Dahan K, Flamant M, Morinière V, Pawtowski A, Heidet L, Lacombe D, Devuyst O, Pirson Y, Antignac C, Knebelmann B.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2429-38. doi: 10.2215/CJN.01220211. Epub 2011 Aug 25.

30.

Recurrence and graft loss after kidney transplantation for henoch-schonlein purpura nephritis: a multicenter analysis.

Kanaan N, Mourad G, Thervet E, Peeters P, Hourmant M, Vanrenterghem Y, De Meyer M, Mourad M, Maréchal C, Goffin E, Pirson Y.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1768-72. doi: 10.2215/CJN.00520111.

31.

Association of PKD2 (polycystin 2) mutations with left-right laterality defects.

Bataille S, Demoulin N, Devuyst O, Audrézet MP, Dahan K, Godin M, Fontès M, Pirson Y, Burtey S.

Am J Kidney Dis. 2011 Sep;58(3):456-60. doi: 10.1053/j.ajkd.2011.05.015. Epub 2011 Jun 29.

PMID:
21719175
32.

Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease.

Jouret F, Lhommel R, Beguin C, Devuyst O, Pirson Y, Hassoun Z, Kanaan N.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1644-50. doi: 10.2215/CJN.06900810. Epub 2011 Jun 23.

33.

Acute abdominal pain and chills in an ADPKD transplant recipient.

Morelle J, Pirson Y, Danse E, Kanaan N.

NDT Plus. 2011 Feb;4(1):71-2. doi: 10.1093/ndtplus/sfq183. Epub 2010 Oct 19. No abstract available.

34.

Outcome of kidney transplantation in type I oral-facial-digital syndrome.

Halleux D, Dahan K, Thauvin-Robinet C, Aral B, Pouteil-Noble C, Devuyst O, Pirson Y.

Transpl Int. 2011 Jun;24(6):e48-50. doi: 10.1111/j.1432-2277.2010.01208.x. Epub 2011 Jan 6. No abstract available.

35.

A homozygous mutation in INVS causing juvenile nephronophthisis with abnormal reactivity of the Wnt/beta-catenin pathway.

Bellavia S, Dahan K, Terryn S, Cosyns JP, Devuyst O, Pirson Y.

Nephrol Dial Transplant. 2010 Dec;25(12):4097-102. doi: 10.1093/ndt/gfq519. Epub 2010 Aug 26.

PMID:
20798123
36.

Extrarenal manifestations of autosomal dominant polycystic kidney disease.

Pirson Y.

Adv Chronic Kidney Dis. 2010 Mar;17(2):173-80. doi: 10.1053/j.ackd.2010.01.003. Review.

PMID:
20219620
37.

Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease.

Kanaan N, Goffin E, Pirson Y, Devuyst O, Hassoun Z.

Am J Kidney Dis. 2010 May;55(5):916-22. doi: 10.1053/j.ajkd.2009.12.023. Epub 2010 Feb 26.

PMID:
20189277
38.

Mild chronic renal failure with a family history of kidney disease.

Hubert F, Dahan K, Cosyns JP, Devuyst O, Pirson Y.

NDT Plus. 2009 Oct;2(5):415-7. doi: 10.1093/ndtplus/sfp068. Epub 2009 Jun 18. No abstract available.

39.

Is peritoneal dialysis a suitable renal replacement therapy in autosomal dominant polycystic kidney disease?

Goffin E, Pirson Y.

Nat Clin Pract Nephrol. 2009 Mar;5(3):122-3. doi: 10.1038/ncpneph1037. Epub 2009 Jan 27.

PMID:
19174770
40.

Does TNF-alpha enhance cystogenesis in ADPKD?

Pirson Y.

Nephrol Dial Transplant. 2008 Dec;23(12):3773-5. doi: 10.1093/ndt/gfn533. Epub 2008 Sep 26. Review. No abstract available.

PMID:
18820281
41.

Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome.

Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M, Pirson Y, Dürrbach A, Grünfeld JP, Knebelmann B, Frémeaux-Bacchi V.

Blood. 2008 Dec 1;112(12):4542-5. doi: 10.1182/blood-2008-03-144691. Epub 2008 Jul 24.

PMID:
18658028
42.

[Engineered kidney tissue: a therapeutic hypothesis?].

Jouret F, Pirson Y.

Med Sci (Paris). 2008 Jun-Jul;24(6-7):561-3. doi: 10.1051/medsci/20082467561. French. No abstract available.

43.

Pauci-immune necrotizing and crescentic glomerulonephritis in a patient with systemic lupus erythematosus.

Fayaz A, Pirson Y, Cosyns JP, Yango J, Lambert M.

Clin Nephrol. 2008 Apr;69(4):290-3.

PMID:
18397704
44.

Genetics of hypercalciuric stone forming diseases.

Devuyst O, Pirson Y.

Kidney Int. 2007 Nov;72(9):1065-72. Epub 2007 Aug 8. Review.

45.

Outcome of kidney transplantation in familial juvenile hyperuricaemic nephropathy.

Labriola L, in Dahan K, Pirson Y.

Nephrol Dial Transplant. 2007 Oct;22(10):3070-3. Epub 2007 Jun 25. No abstract available.

PMID:
17595184
46.

Advances in genetic diseases of the kidney: impact on renal medicine.

Pirson Y.

Acta Clin Belg. 2007 Mar-Apr;62(2):83-7. Review. No abstract available.

PMID:
17547288
47.

Autosomal dominant polycystic kidney disease.

Torres VE, Harris PC, Pirson Y.

Lancet. 2007 Apr 14;369(9569):1287-1301. doi: 10.1016/S0140-6736(07)60601-1. Review.

PMID:
17434405
48.

Identification of current smokers among renal transplant recipients.

Nguyen PT, Galanti L, Pirson Y, Jadoul M.

Nephrol Dial Transplant. 2007 Jul;22(7):1974-8. Epub 2007 Mar 29.

PMID:
17400560
49.

Cerebral aneurysms.

Torres VE, Pirson Y, Wiebers DO.

N Engl J Med. 2006 Dec 21;355(25):2703-4; author reply 2705. No abstract available.

PMID:
17186587
50.

Atypical haemolytic uraemic syndrome associated with a hybrid complement gene.

Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship TH.

PLoS Med. 2006 Oct;3(10):e431.

Supplemental Content

Loading ...
Support Center